Literature DB >> 26419508

Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia.

E Andersson1,2, H Kuusanmäki1,3, S Bortoluzzi1, S Lagström3, A Parsons3, H Rajala1,2, A van Adrichem3, S Eldfors3, T Olson4, M J Clemente5, A Laasonen2, P Ellonen3, C Heckman3, T P Loughran4, J P Maciejewski5, S Mustjoki1,2,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26419508      PMCID： PMC4814354          DOI： 10.1038/leu.2015.263

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  STAT3 mutations are highly specific for large granular lymphocytic leukemia.

Authors:  A Fasan; W Kern; V Grossmann; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2012-12-04       Impact factor: 11.528

3.  STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia.

Authors:  R S Ohgami; L Ma; J D Merker; B Martinez; J L Zehnder; D A Arber
Journal:  Leukemia       Date:  2013-04-08       Impact factor: 11.528

Review 4.  Large granular lymphocyte leukemia.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

5.  The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6.

Authors:  T Zhang; W H Kee; K T Seow; W Fung; X Cao
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Rajala; Samuli Eldfors; Heikki Kuusanmäki; Arjan J van Adrichem; Thomas Olson; Sonja Lagström; Emma I Andersson; Andres Jerez; Michael J Clemente; Yiyi Yan; Dan Zhang; Andy Awwad; Pekka Ellonen; Olli Kallioniemi; Krister Wennerberg; Kimmo Porkka; Jaroslaw P Maciejewski; Thomas P Loughran; Caroline Heckman; Satu Mustjoki
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

7.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

Authors:  P K Epling-Burnette; J H Liu; R Catlett-Falcone; J Turkson; M Oshiro; R Kothapalli; Y Li; J M Wang; H F Yang-Yen; J Karras; R Jove; T P Loughran
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

8.  STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.

Authors:  Andres Jerez; Michael J Clemente; Hideki Makishima; Hanna Koskela; Francis Leblanc; Kwok Peng Ng; Thomas Olson; Bartlomiej Przychodzen; Manuel Afable; Ines Gomez-Segui; Kathryn Guinta; Lisa Durkin; Eric D Hsi; Kathy McGraw; Dan Zhang; Marcin W Wlodarski; Kimmo Porkka; Mikkael A Sekeres; Alan List; Satu Mustjoki; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2012-08-02       Impact factor: 22.113

9.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.

Authors:  Camilla Pilati; Mohamed Amessou; Michel P Bihl; Charles Balabaud; Jeanne Tran Van Nhieu; Valérie Paradis; Jean Charles Nault; Tina Izard; Paulette Bioulac-Sage; Gabrielle Couchy; Karine Poussin; Jessica Zucman-Rossi
Journal:  J Exp Med       Date:  2011-06-20       Impact factor: 14.307

10.  A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.

Authors:  Guangzhen Hu; Thomas E Witzig; Mamta Gupta
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240
View more
  29 in total

Review 1.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

2.  Subclonal STAT3 mutations solidify clonal dominance.

Authors:  Cassandra M Kerr; Michael J Clemente; Peter W Chomczynski; Bartlomiej Przychodzen; Yasunobu Nagata; Vera Adema; Valeria Visconte; Alan E Lichtin; Satu Mustjoki; Tomas Radivoyevitch; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Blood Adv       Date:  2019-03-26

3.  Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia.

Authors:  Elizabeth A Morgan; Mark N Lee; Daniel J DeAngelo; David P Steensma; Richard M Stone; Frank C Kuo; Jon C Aster; Christopher J Gibson; R Coleman Lindsley
Journal:  Blood Adv       Date:  2017-09-13

4.  Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Authors:  Alexandra Nagy; Aparna Bhaduri; Nahid Shahmarvand; Jahanbanoo Shahryari; James L Zehnder; Roger A Warnke; Tariq Mughal; Siraj Ali; Robert S Ohgami
Journal:  Blood Adv       Date:  2018-03-13

5.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Authors:  Tammy Linlin Song; Maarja-Liisa Nairismägi; Yurike Laurensia; Jing-Quan Lim; Jing Tan; Zhi-Mei Li; Wan-Lu Pang; Atish Kizhakeyil; Giovani-Claresta Wijaya; Da-Chuan Huang; Sanjanaa Nagarajan; Burton Kuan-Hui Chia; Daryl Cheah; Yan-Hui Liu; Fen Zhang; Hui-Lan Rao; Tiffany Tang; Esther Kam-Yin Wong; Jin-Xin Bei; Jabed Iqbal; Nicholas-Francis Grigoropoulos; Siok-Bian Ng; Wee-Joo Chng; Bin-Tean Teh; Soo-Yong Tan; Navin Kumar Verma; Hao Fan; Soon-Thye Lim; Choon-Kiat Ong
Journal:  Blood       Date:  2018-07-27       Impact factor: 22.113

6.  Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia.

Authors:  Toru Kawakami; Nodoka Sekiguchi; Jun Kobayashi; Tatsuya Imi; Kazuyuki Matsuda; Taku Yamane; Sayaka Nishina; Yasushi Senoo; Hitoshi Sakai; Toshiro Ito; Tomonobu Koizumi; Makoto Hirokawa; Shinji Nakao; Hideyuki Nakazawa; Fumihiro Ishida
Journal:  Blood Adv       Date:  2018-10-23

7.  Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.

Authors:  Heikki Kuusanmäki; Olli Dufva; Elina Parri; Arjan J van Adrichem; Hanna Rajala; Muntasir M Majumder; Bhagwan Yadav; Alun Parsons; Wing C Chan; Krister Wennerberg; Satu Mustjoki; Caroline A Heckman
Journal:  Oncotarget       Date:  2017-10-31

8.  Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis.

Authors:  Xi Wang; Chunyan Dai; Yifei Yin; Lin Wu; Weiyang Jin; Yufei Fu; Zhe Chen; Ke Hao; Bin Lu
Journal:  J Zhejiang Univ Sci B       Date:  2021-06-15       Impact factor: 3.066

Review 9.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  A guilt-by-association mutation network in LGL leukemia.

Authors:  Emma I Andersson; Alessandro Coppe; Stefania Bortoluzzi
Journal:  Oncotarget       Date:  2017-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.